Targacept has announced that AstraZeneca will pursue the development of the company’s candidate AZD1446 as a treatment for Alzheimer’s disease.

AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor developed through a research collaboration conducted by Targacept and AstraZeneca.

Under the terms of a 2005 collaborative research and license agreement, AstraZeneca took responsibility for further development and potential commercialisation of AZD1446.

The drug will now move into a Phase II trial as an additional treatment to donepezil for patients with mild to moderate Alzheimer’s.

Targacept President and CEO J Donald deBethizy said that the planned evaluation of AZD1446 as an augmentation treatment in Alzheimer’s complements Targacept’s ongoing Phase IIb study of AZD3480 as a monotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.